REACH Interview Series: Scott Sonenshein

The Reach Interview Series is an informal dialogue between me and respected thought leaders around the theme of my new book,  Reach: A New Strategy to Help You Step Outside Your Comfort Zone, Rise to the Challenge and Build Confidence

Scott Sonenshein is a Professor at Rice University and the author of the new book Stretch: Unlock the Power of Less – and Achieve More than You Ever Imagined. He also happens to be a personal friend!  In this edition of the comfort zone series, we talk about the challenges of writing a popular book as an academic and how it can really force us to reach outside our comfort zones in multiple ways.


AVAILABLE NOW

Reach A New Strategy to Help You Step Outside Your Comfort Zone 

Prescriptive and based not only on my groundbreaking research but on my own quest to get out of my comfort zone, Reach will help you take the thing you are most afraid of doing and make it a proud part of your personal repertoire.

Learn More

Related Posts

REACH Interview Series: Justin Kang

REACH Interview Series: Justin Kang

With today’s edition of the Reach Interview series, we decided to stay local – focusing here in Boston on one of the city’s young rising stars of civic leadership.

Read More

Helping Foreign Students Speak Up

Helping Foreign Students Speak Up

If academic institutions had water coolers and professors liked to make small talk, one of the hottest topics on the agenda would be how to get foreign students to participate in class.

Read More

REACH Interview Series: Paul Liberman

REACH Interview Series: Paul Liberman

Paul Liberman is co-founder and COO of DraftKings, a leading provider of daily fantasy sports.

Read More

In a New Culture Wait to Cut to the Chase

In a New Culture Wait to Cut to the Chase

Xavier Frei wanted to get down to business. A Zurich-born manager with 10 years’ experience working in Germany and Switzerland, Xavier had just landed a few days ago in Monterrey, Mexico, at a small pharmaceutical company that was recently purchased by Xavier’s company, a major European pharmaceutical firm.

Read More